Solvated form of trilaciclib dihydrochloride
The solvated form of trilaciclib dihydrochloride trifluoroethanol in crystalline form addresses the need for high purity and stability, enabling effective industrial-scale production and improved treatment efficacy for trilaciclib dihydrochloride, particularly in treating small cell lung cancer and triple-negative breast cancer.
Patent Information
- Application Number
- PCT/IB2024/055129
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-29
- Filing Date
- 2024-05-27
- Publication Date
- 2024-12-05
AI Technical Summary
There is a need for a form of trilaciclib dihydrochloride with high purity and stability, as well as an industrial-scale production process that allows for control of the impurity profile, to enhance its efficacy in treating conditions like small cell lung cancer and triple-negative breast cancer.
A solvated form of trilaciclib dihydrochloride trifluoroethanol solvate in crystalline form is developed, along with two alternative processes that involve suspending trilaciclib in a mixture of organic solvent and trifluoroethanol, adding hydrochloric acid, and controlling temperature and stirring times to achieve high purity and stability, facilitating industrial-scale production and impurity profile control.
The solvated form exhibits high purity, stability, and solubility, enabling effective control of the impurity profile and suitable for industrial-scale production, thereby improving the pharmaceutical's efficacy and usability in clinical treatments.
Smart Images

Figure IB2024055129_05122024_PF_FP_ABST
Abstract
Description
[0001] SOLVATED FORM OF TRILACICLIB DIHYDROCHLORIDE
[0002] TECHNICAL FIELD
[0003] The present invention refers to the technical field of active pharmaceutical ingredients. Specifically, the present invention concerns a solvated form of the active ingredient trilaciclib dihydrochloride, in particular trilaciclib dihydrochloride trifluoroethanol solvate of formula II in crystalline form, and two alternative preparation processes.
[0004] PRIOR ART
[0005] Trilaciclib dihydrochloride is an active ingredient with formula I Formula I .
[0006] This active ingredient, as is known, is capable of temporarily stopping normal cells to prevent chemotherapy-induced myelosuppression and therefore improve anti-tumor efficacy. It can be used, for example, in patients with small cell lung cancer (SCLC) receiving topotecan-based chemotherapy.
[0007] In particular, US 8,598,186; US 8,598,197; US 9,957,276; US 10,189,849 and US 10,189,850 and the corresponding WO 2012 / 061156 describe a class of inhibitors of cyclin-dependent N- (heteroaryl ) - pyrrolo [ 3 , 2-d] pyrimidin-2-amine kinases including 2 ’ — ( ( 5— ( 4- methylpiperazyl-l-yl ) pyridin-2-yl ) amino ) -7 ' , 8 ' -dihydro- 6 ' H- spiro [ cyclohexane- 1 , 9'-pyrazino[l',2' :l,5] pyrrolo [ 2 , 3- d] pyrimidin] - 6 ' -one (Compound 1) Compound 1. Additionally, US 2019 / 135820 and WO 2020 / 041770 describe the processes for the synthesis of Compound 1 . Compound 1 , referred to as "G1T28" or " trilaciclib" , is used in human clinical trials for the treatment of triple breast cancer negative in combination with standard of treatment for neoadj uvant treatment of breast cancer . There is therefore a felt need to have a form of the active ingredient trilaciclib that is characteri zed by high purity and stability, as well as a process to produce it that is easily industriali zed and that allows to control the impurity profile associated with the product obtained .
[0008] SUMMARY OF THE INVENTION
[0009] The Applicant has now found a new solvated form of trilaciclib, in particular trilaciclib dihydrochloride tri fluoroethanol solvate of formula I I in crystalline form, which satis fies the aforementioned needs .
[0010] Therefore , in accordance with a first aspect , the present invention concerns trilaciclib dihydrochloride tri fluoroethanol solvate of formula I I in crystalline form Formula I I , according to the attached claims .
[0011] In accordance with a second aspect , the present invention concerns a process for obtaining trilaciclib dihydrochloride tri fluoroethanol solvate of formula I I in crystalline form Formula I I , according to the attached claims . In accordance with a third aspect , the present invention concerns a further process for obtaining trilaciclib dihydrochloride tri fluoroethanol solvate of formula I I in crystalline form Formula I I according to the attached claims .
[0012] Advantageously, the solvated form of trilaciclib dihydrochloride , in particular trilaciclib dihydrochloride tri fluoroethanol solvate of formula I I in crystalline form, is characteri zed by high purity and stability, as well as high solubility . The solvated form of this active ingredient with such characteristics is advantageously obtained through the processes according to the present invention . The processes according to the present invention in fact allow an advantageous control of the impurity profile on the final product . Furthermore , the two processes o f the invention are both suitable for implementation on an industrial scale as they can be easily industriali zed .
[0013] Further aspects , characteristics and advantages of the invention will be evident from the following detailed description .
[0014] BRIEF DESCRIPTION OF THE FIGURES
[0015] Figure 1 shows the X-ray di f fraction (XRPD) spectrum of trilaciclib dihydrochloride tri fluoroethanol solvate of the invention;
[0016] Figure 2 shows the results of the TGA thermogravimetric analysis performed on trilaciclib dihydrochloride tri fluoroethanol solvate of the invention;
[0017] Figure 3 shows the1H-NMR hydrogen nuclear magnetic resonance spectrum of trilaciclib dihydrochloride trifluoroethanol solvate of the invention .
[0018] DETAILED DESCRIPTION For the purposes of the invention, definitions of some terms and / or expressions used in this description and in the claims will be provided below.
[0019] A first aspect of the invention therefore concerns trilaciclib dihydrochloride trifluoroethanol solvate of formula II in crystalline form Formula II having a characteristic XRPD dif f ractogram comprising at least one characteristic peak expressed in 2-Theta values (20) selected from 5,7°±0,2°, 9,l°±0,2°, 13,8°±0,2°, 16,6°±0,2°, 19,0°±0,2°, 20,6°±0,2°,
[0020] 27, 7 °±0, 2 ° .
[0021] Preferably, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram comprising at least two characteristic peaks expressed in 2-Theta values (20) selected from 5,7°±0,2°, 9,l°±0,2°, 13,8°±0,2°, 16,6°±0,2°, 19,0°±0,2°, 20,6°±0,2°,
[0022] 27, 7 °±0, 2 ° .
[0023] More preferably, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram comprising at least three characteristic peaks expressed in 2-Theta values (20) selected from 5,7°±0,2°, 9,l°±0,2°, 13,8°±0,2°, 16,6°±0,2°, 19,0°±0,2°, 20,6°±0,2°,
[0024] 27, 7 °±0, 2 ° .
[0025] Even more preferably, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram comprising at least four characteristic peaks expressed in 2-Theta values (20) selected from 5,7°±0,2°, 9,l°±0,2°, 13,8°±0,2°, 16,6°±0,2°, 19,0°±0,2°, 20,6°±0,2°,
[0026] 27, 7 °±0, 2 ° .
[0027] According to a preferred embodiment of the invention, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram having the following characteristic peaks expressed in 2-Theta values (20) 5,7°±0,2°, 9,l°±0,2°, 13,8°±0,2°, 16,6°±0,2°, 19,0°±0,2°, 20,6°±0,2°, 27,7°±0,2°. In addition, as additional peak(s) , the solvate of formula II in crystalline form may further comprise at least one characteristic peak expressed in 2-Theta values (20) selected from ll,5°±0,2°, 14,8°±0,2°, 17,3°±0,2°, 18,2°±0,2°.
[0028] The solvated form according to the invention, i.e. trilaciclib dihydrochloride trifluoroethanol solvate of formula II, has a molar ratio between trilaciclib dihydrochloride and trifluoroethanol equal to 1:1.
[0029] With reference to the final pharmaceutical formulations of trilaciclib, administered intravenously, the active ingredient trilaciclib dihydrochloride trifluoroethanol solvate of formula II of the present invention is particularly advantageous thanks to its high solubility compared to other less soluble forms, for example trilaciclib free base .
[0030] Another aspect of the invention concerns a process for obtaining trilaciclib dihydrochloride trifluoroethanol solvate of formula II in crystalline form Formula II as defined above, comprising the steps of: a' ) suspending trilaciclib base in a mixture of organic solvent and trifluoroethanol and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or a' ' ) suspending trilaciclib in the form of a salt in a mixture of organic solvent and trifluoroethanol, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or a' ' ' ) suspending trilaciclib dihydrochloride in a mixture of organic solvent and trifluoroethanol, obtaining a suspension of trilaciclib dihydrochloride ; b) heating the suspension referred to in step a' ) , a' ' ) or a' ' ' ) to a temperature between 30° and 75°C obtaining a suspension; c) keeping the suspension referred to in step b) stirring for 2-30 hours ; d) cooling the suspension obtained in step c) to a temperature between 0°C and 30°C, preferably between 15°C and 30°C, more preferably between 22°C and 28°C; e) isolating trilaciclib solvate of formula II in crystalline form. With reference to step a' ) , a' ' ) or a' ' ' ) , trilaciclib is preferably trilaciclib free base or a salt thereof. Preferably the trilaciclib salt is dihydrochloride or trifluoroacetate.
[0031] According to a preferred aspect of the invention, in step a' ) , a' ' ) or a' ' ' ) , the ratio between trilaciclib : organic solvent : trifluoroethanol is between 1:20:8 and 1:40:12 by volume . Preferably, said ratio is selected from 1:25:9 and 1:35:11 by volume. According to a particularly preferred aspect, said ratio is 1:30:11 by volume.
[0032] According to another preferred aspect, the organic solvent referred to in step a' ) , a' ' ) or a' ' ') is preferably selected from esters or ethers. When the organic solvent is an ester, preferably it is ethyl acetate. When the organic solvent is an ether, it is preferably an ether of formula OR1R2, in which the R1 and R2 groups are selected, independently of each other, from C1-C6 alkyl, linear or branched, and C3-C6 cycloalkyl. According to a preferred aspect, when the solvent is an ether, it is selected from methyl t-butyl ether and cyclopentyl methyl ether.
[0033] As regards steps a' ) and a' ') , preferably the hydrochloric acid is anhydrous hydrochloric acid dissolved in an organic solvent selected from alcohols, ethers, esters or mixtures thereof. When anhydrous hydrochloric acid is dissolved in an alcohol, this is preferably isopropanol. When anhydrous hydrochloric acid is dissolved in an ether, this is preferably cyclopentyl methyl ether. When anhydrous hydrochloric acid is dissolved in an ester, this is preferably ethyl acetate . According to a preferred aspect, the concentration of anhydrous hydrochloric acid in solvent is between 1 M and 5 M, preferably the concentration of hydrochloric acid in ethyl acetate is between 2 M and 4 M. According to an even more preferred aspect, the concentration of hydrochloric acid in ethyl acetate is 3 M. Advantageously, the addition of organic solvent in step a' ) , a' ' ) , or a' ' ' ) allows the precipitation of the product to be obtained in reduced times and therefore the purity of the product is higher, since the possibility of formation of the impurities themselves is reduced .
[0034] According to a preferred aspect of the invention, the heating temperature referred to in step b) varies depending on the form of trilaciclib loaded in step a) , in particular it is higher if the loaded trilaciclib is dihydrochloride and lower if the trilaciclib loaded is in basic form. If the trilaciclib used in step a) is in the form of a dihydrochloride, the temperature referred to in step b) is preferably comprised between 60°-70°C, more preferably between 62°-68°C. If the trilaciclib used in step a) is in the base form, the temperature referred to in step b) is comprised between 30°- 50°C, more preferably between 38°-42°C.
[0035] According to a preferred aspect of the reaction, if the trilaciclib used in step a) is in the form of di-hydrochloride, the hot keeping time referred to in step c) is comprised between 10 and 26 hours, more preferably between 15 and 21 hours. If the trilaciclib used in step a) is in base form, the hot keeping time referred to in step c) is preferably comprised between 4 and 20 hours, more preferably between 10 and 14 hours.
[0036] As regards the isolation step e) , this step is preferably carried out by filtration.
[0037] According to a preferred aspect, the process of the invention further comprises a step f) : f) drying the solvate of formula II obtained in step e) under vacuum at a temperature between 35°C and 55°C, preferably at a temperature between 40°C and 50°C, more preferably between 42°C and 48 °C. According to another preferred aspect, the drying step f) takes place for a time between 10 and 48 hours, preferably between 12 and 24 hours .
[0038] According to another preferred aspect, the drying step f) takes place at a temperature between 35°C and 55°C, preferably at a temperature between 40°C and 50°C, more preferably between 42°C and 48°C, and for a time between 10 and 48 hours, preferably between 12 and 24 hours .
[0039] Another aspect of the invention concerns a further alternative process for obtaining the solvate of formula II in crystalline form. In particular, according to another aspect, the invention concerns a process for obtaining the solvate of formula II in crystalline form Formula II as defined above, including the steps of: m' ) suspending trilaciclib base in trifluoroethanol and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ) suspending trilaciclib in the form of a salt in trifluoroethanol, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ' ) suspending trilaciclib dihydrochloride in trifluoroethanol, obtaining a suspension of trilaciclib dihydrochloride; n) adding the suspension of trilaciclib dihydrochloride referred to in step m' ) , m' ' ) or m' ' ' ) to an organic solvent so as to precipitate trilaciclib as trilaciclib solvate of formula II in crystalline form; o) isolating trilaciclib solvate of formula II in crystalline form. With reference to step m' ) , m' ' ) or m' ' ' ) , trilaciclib is preferably trilaciclib free base or a salt thereof. Preferably the trilaciclib salt is dihydrochloride or trifluoroacetate. According to a preferred aspect of the invention, in step m' ) , m' ' ) or m' ' ' ) the ratio between trilaciclib and trifluoroethanol is between 1:4 and 1:8 by volume, preferably said ratio is between 1:5 and 1:7.
[0040] According to another preferred aspect of the invention, the passage m' ) , m' ' ) or m' ' ' ) is carried out at a temperature between 15°-35°C.
[0041] As regards steps m' ) and m' ' ) , preferably the hydrochloric acid is anhydrous hydrochloric acid dissolved in an organic solvent selected from alcohols, ethers, esters or mixtures thereof. When the anhydrous hydrochloric acid is dissolved in an alcohol, this is preferably selected from methanol, ethanol, isopropanol or mixtures thereof, more preferably the anhydrous hydrochloric acid is dissolved in isopropanol. When anhydrous hydrochloric acid is dissolved in an ether, this is preferably cyclopentyl methyl ether. When anhydrous hydrochloric acid is dissolved in an ester, this is preferably ethyl acetate, isopropyl acetate or mixtures thereof. Even more preferably, anhydrous hydrochloric acid is dissolved in ethyl acetate. According to a preferred aspect, the concentration of anhydrous hydrochloric acid in solvent is between 1 M and 5 M, preferably the concentration of anhydrous hydrochloric acid in ethyl acetate is between 2 M and 4 M. According to an even more preferred aspect, the concentration of anhydrous hydrochloric acid in ethyl acetate is 3 M.
[0042] As regards step n) , preferably the ratio between the suspension obtained in step m' ) , m' ' ) or m' ' ' ) and the organic solvent is between 1:1 and 1:3 by volume, preferably such ratio is 1:2 by volume .
[0043] According to a preferred aspect, the addition referred to in step n) takes place at a temperature between 15° and 35°C.
[0044] With reference to step n) , the organic solvent is preferably selected from esters, preferably ethyl acetate, and ethers, preferably an ether of formula OR1R2, wherein the R1 and R2 groups are selected, independently from each other, from C1-C6 alkyl, linear or branched, and C3-C6 cycloalkyl.
[0045] According to a preferred aspect, when the solvent is an ether, it is cyclopentyl methyl ether.
[0046] Preferably, when the solvent is an ester, it is selected from ethyl acetate and isopropyl acetate.
[0047] Advantageously, step n) is carried out in such a way as to dilute the suspension of trilaciclib di-hydrochloride obtained in the previous step m' ) , m' ' ) or m' ' ' ) , so as to obtain the precipitation of trilaciclib dihydrochloride trifluoroethanol solvate of formula II and therefore increase the yield of the process.
[0048] As regards the isolation step o) , this step is preferably carried out by filtration.
[0049] According to a preferred aspect, the process of the invention further comprises a step p) : p) drying the solvate of formula II obtained in step o) under vacuum at a temperature between 35°C and 55°C, preferably at a temperature between 40°C and 50°C, more preferably between 42°C and 48 °C.
[0050] According to another preferred aspect, the drying step o) takes place for a time between 10 and 48 hours, preferably between 12 and 24 hours .
[0051] According to another preferred aspect, the drying step o) takes place at a temperature between 35°C and 55°C, preferably at a temperature between 40°C and 50°C, more preferably between 42°C and 48°C, and for a time between 10 and 48 hours, preferably between 12 and 24 hours .
[0052] The above is intended as an example and not as a limitation. Furthermore, the person skilled in the art will be able to understand what modifications can be made without departing from the scope of the present invention. EXAMPLES
[0053] The present description will be better illustrated in the following examples which are only for illustrative and non-limiting purposes. Example 1. Trilaciclib dihydrochloride trifluoroethanol solvate by trilaciclib dihydrochloride.
[0054] 500 mg of trilaciclib dihydrochloride was dissolved in 20 ml of a mixture made up of 5 ml of trifluoroethanol and 15 ml of ethyl acetate. The mass was kept under stirring at 65°C for 18 hours. The temperature was lowered to 25°C, and stirring was maintained for 30 minutes. The solid product was filtered and washed with 2 ml of ethyl acetate. The resulting wet product was dried in a vacuum oven at 45°C for 16 hours. The product was isolated with a yield of 85%.
[0055] Example 2. Trilaciclib dihydrochloride trifluoroethanol solvate by trilaciclib free base.
[0056] 500 mg of trilaciclib base was suspended in 20 ml of a mixture of 5 ml of trifluoroethanol and 15 ml of ethyl acetate. 0.4 ml of HC1 in 3 M ethyl acetate was added.
[0057] The mass was kept under stirring at 40°C for 12 hours.
[0058] After bringing the temperature back to 25°C, the mass was kept under stirring for 60 minutes and then filtered. The product was washed with 2 ml of ethyl acetate and dried in a vacuum oven at 45°C for 16 hours. The molar yield was 86%.
Claims
CLAIMS :
1. Trilaciclib dihydrochloride trifluoroethanol solvate of formulaII in crystalline formFormula II having a characteristic XRPD dif f ractogram comprising at least one characteristic peak expressed in 2-Theta (20) values selected from 5.7°±0.2°, 9.1°±0.2°, 13.8°±0.2°, 16.6°±0.2°, 19.0°±0.2°, 20.6°±0.2°, 27.7°±0.2° .
2. Trilaciclib according to claim 1, having a characteristic XRPD dif f ractogram comprising at least two characteristic peaks expressed in 2-Theta (20) values selected from 5.7°±0.2°, 9.1°±0.2°, 13.8°±0.2°, 16.6°±0.2°, 19.0°±0.2°, 20.6°±0.2°, 27.7° ±0.2° .
3. Trilaciclib according to claim 1, having a characteristic XRPD dif f ractogram comprising at least three characteristic peaks expressed in 2-Theta (20) values selected from 5.7°±0.2°, 9.1°±0.2° , 13.8°±0.2°, 16.6°±0.2°, 19.0°±0.2°, 20.6°±0.2°, 27.7° ±0.2° .
4. Process for obtaining trilaciclib dihydrochloride trifluoroethanol solvate of formula II in crystalline formFormula II as defined in any one of claims 1-3, comprising the steps of: a' ) suspending trilaciclib base in a mixture of organic solvent and trifluoroethanol and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or a' ' ) suspending trilaciclib in the form of a salt in a mixture of organic solvent and trifluoroethanol, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, ora' ' ' ) suspending trilaciclib dihydrochloride in a mixture of organic solvent and trifluoroethanol, obtaining a suspension of trilaciclib dihydrochloride ; b) heating the suspension referred to in step a' ) , a' ' ) or a' ' ' ) to a temperature ranging from 30° to 75°C to obtain a suspension; c) maintaining the suspension referred to in step b) under stirring for 2-30 hours; d) cooling the suspension obtained in step c) to a temperature comprised between 0°C and 30°C, preferably between 15°C and 30°C, more preferably between 22°C and 28°C; e) isolating trilaciclib solvate of formula II in crystalline form.
5. Process according to claim 4, wherein the trilaciclib salt of step a' ' ) is trilaciclib trifluoroacetate.
6. Process according to any one of claims 4-5, wherein the organic solvent referred to in step a' ) , a' ' ) , a' ' ' ) is selected from esters, preferably ethyl acetate and ethers, preferably an ether of formula OR1R2, wherein R1 and R2 groups are independently selected from linear or branched C1-C6 alkyl and C3-C6 cycloalkyl.
7. Process for obtaining trilaciclib dihydrochloride trifluoroethanol solvate of formula II in crystalline formFormula II as defined in any one of claims 1-3, comprising the steps of: m' ) suspending trilaciclib base in trifluoroethanol and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ) suspending trilaciclib in the form of a salt in trifluoroethanol, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ' ) suspending trilaciclib dihydrochloride in trifluoroethanol, obtaining a suspension of trilaciclib dihydrochloride;n) adding the suspension of trilaciclib dihydrochloride referred to in step m' ) , m' ' ) or m' ' ' ) to an organic solvent so as to precipitate trilaciclib as trilaciclib solvate of formula II in crystalline form; o) isolating trilaciclib solvate of formula II in crystalline form.
8. Process according to claim 7, wherein the salt of step m' ' ) is trilaciclib trifluoroacetate .
9. Process according to any one of claims 7-8, wherein in step m' ) , m' ' ) or m' ' ' ) the ratio between trilaciclib and trifluoroethanol is comprised between 1:4 and 1:8 by volume, preferably said ratio is between comprised 1:5 and 1:7.
10. Process according to any one of claims 7-9, wherein the organic solvent referred to in step n) is selected from esters, preferably ethyl acetate, and ethers, preferably an ether of formula OR1R2, wherein the groups R1 and R2 are selected from, independently of each other, linear or branched C1-C6 alkyl and C3-C6 cycloalkyl.
Citation Information
Patent Citations
CDK inhibitors
WO2012061156A1
Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
WO2018005865A1
Morphic forms of trilaciclib and methods of manufacture thereof
WO2021257587A1
Solid state forms of trilaciclib and of trilaciclib salts
WO2022076779A1
